Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2017-05-04 Earnings Release
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2017, reporting the results of operations and financial condition for the third quarter of fiscal year 2017. It includes a press release announcing these results and information about a planned Special Meeting of Stockholders to seek approval for issuing additional shares. The document references a press release (Exhibit 99.1) and a preliminary proxy statement filed for the Special Meeting. The content primarily focuses on announcing quarterly financial results and related corporate actions, typical of an Earnings Release. The document length is 5841 characters, which is consistent with an 8-K earnings release filing. It is not a full annual or interim report, nor a proxy statement itself, but an 8-K current report announcing quarterly results and related events. Therefore, the best classification is Earnings Release (ER).
2017-05-04 English
FORM 8-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 4, 2017, by pSivida Corp. It announces the company's third quarter fiscal year 2017 results via a press release (Exhibit 99.1) and discusses a planned Special Meeting of Stockholders to seek approval for refreshing the capacity to issue additional shares. The document includes a solicitation for proxy votes related to the Special Meeting and mentions a definitive proxy statement to be filed. The content focuses on proxy solicitation and shareholder meeting information rather than the actual proxy statement or detailed financial results. The document is not the proxy statement itself but a current report announcing related events and solicitation materials. Therefore, the filing best fits the category of Proxy Solicitation & Information Statement (PSI). The document length (5845 characters) and content support this classification with high confidence.
2017-05-04 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a preliminary proxy statement for a special meeting of stockholders of pSivida Corp. It includes detailed information about proposals to be voted on, such as ratification of share issuance and amendment to the certificate of incorporation, as well as voting instructions and other meeting-related information. The document is not an annual report, earnings release, or other financial report but is clearly a proxy solicitation document intended to provide shareholders with information to vote on corporate matters at a meeting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is the actual proxy statement, not just an announcement or notice.
2017-05-04 English
SC 13G
Major Shareholding Notification
2017-04-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a new funded feasibility study agreement entered into by the company, which is an update on business activities rather than a financial report or detailed management discussion. The document length is short (2409 characters) and it does not contain financial statements or detailed analysis. It is not an announcement of a report publication but a standalone event disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2017-03-06 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans, such as stock options and restricted stock units. The text includes detailed information about the securities to be registered under the pSivida Corp. 2016 Long Term Incentive Plan and inducement awards to the CEO. It references incorporation by reference of prior filings like 10-K and 10-Q but is itself a registration statement for securities issuance, not a financial report or earnings release. This type of filing is related to capital structure changes and financing activities, specifically the registration of new shares for issuance under stock plans. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a proxy statement, but a full registration statement.
2017-02-22 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.